{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:47:36Z","timestamp":1792320456821,"version":"4.4.0"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,8,10]],"date-time":"2009-08-10T00:00:00Z","timestamp":1249862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:sec><jats:label\/><jats:p><jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Albendazole is used in several anthelminthic drug programs.<\/jats:p><jats:p>\u2022\u2003It may be necessary to include sectors of the community (such as breastfeeding women) not previously involved in community or clinical programmes (e.g. filariasis, hydatid disease) to achieve a reasonable level of elimination of the worm.<\/jats:p><jats:p>\u2022\u2003However, there are no studies in which the amount of the drug and\/or its metabolites in the milk of lactating women was analysed, so as to assess the possible exposure of the breastfed infant.<\/jats:p><jats:p><jats:bold>WHAT THIS STUDY ADDS<\/jats:bold><\/jats:p><jats:p>\u2022\u2003In the present study, the concentrations of albendazole and its active metabolite (albendazole sulphoxide) were analysed in the milk of lactating women through 36\u2003h after administration of a single (400\u2003mg) oral dose of albendazole.<\/jats:p><jats:p>\u2022\u2003Albendazole was barely secreted in milk as such.<\/jats:p><jats:p>\u2022\u2003On the other hand, albendazole sulphoxide was analysed through the 36\u2003h of the study, and it was concluded that albendazole and albendazole sulphoxide attain levels in breast milk that are unlikely to be considered harmful for the breastfed infant.<\/jats:p><jats:p>\u2022\u2003These findings would help in deciding whether to involve breastfeeding mothers in albendazole mass drug administration programmes.<\/jats:p><\/jats:sec><jats:sec><jats:title>AIMS<\/jats:title><jats:p>Albendazole (ABZ) is used in several anthelminthic drug programmws. ABZ side\u2010effects are generally mild, but ABZ\u2010induced pancytopenia may be serious. In filariasis programmes, it may be necessary to administer ABZ to breastfeeding women. Few data are available on safety of ABZ for breastfed infants. In addition, the pharmacokinetics of ABZ and its metabolites in human milk is insufficiently investigated. The aim was to study pharmacokinetics of ABZ and its metabolites [ABZ sulphoxide (ABSX) and ABZ sulphone] in the breast milk lactating women after one single oral dose of ABZ.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Thirty\u2010three lactating women (age 18\u201340 years) participated in the study. They received a single oral 400\u2010mg dose of ABZ. Five milk samples were taken at 0, 6, 12, 24 and 36\u2003h. One serum sample was taken after 6\u2003h. Samples were analysed using high\u2010performance liquid chromatography and pharmacokinetic analysis was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>ABZ was detectable in milk samples 6\u2003h after the oral dose. The mean concentration of serum ABZ was 63.7 \u00b1 11.9\u2003ng\u2003ml<jats:sup>\u22121<\/jats:sup>. The pharmacokinetic parameters for ABSX were calculated as follows: 351.9 \u00b1 32.4\u2003ng\u2003ml<jats:sup>\u22121<\/jats:sup>, 6.9 \u00b1 0.5\u2003h, 12.4 \u00b1 2.2\u2003h and 5190.3 \u00b1 482.8\u2003ng*h\u2003ml<jats:sup>\u22121<\/jats:sup>for<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>,<jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub>,<jats:italic>t<\/jats:italic><jats:sub>\u00bd<\/jats:sub>and AUC<jats:sub>0\u201336<\/jats:sub>, respectively. The milk\u2010to\u2010serum ratios (range) for ABZ and ABSX were 0.9 (0.2\u20136.5) and 0.6 (0.1\u20131.5), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>After an oral dose of 400\u2003mg, ABZ and ABSX attain low concentrations in breast milk that are unlikely to be considered harmful for the breastfed infant.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2009.03524.x","type":"journal-article","created":{"date-parts":[[2009,8,10]],"date-time":"2009-08-10T09:42:21Z","timestamp":1249897341000},"page":"737-742","source":"Crossref","is-referenced-by-count":25,"title":["Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole"],"prefix":"10.1111","volume":"68","author":[{"given":"Ahmed M.","family":"Abdel\u2010tawab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essam A.","family":"Ghazaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged","family":"El\u2010Setouhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.3.451"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-1-200607040-00009"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200212000-00008"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-4758(99)01486-6"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)00973-9"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4269\/ajtmh.2003.68.568","article-title":"Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000","volume":"68","author":"McLaughlin SI","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2005.72.291"},{"key":"e_1_2_6_9_2","first-page":"594","article-title":"Drug use during breast\u2010feeding","volume":"10","author":"Anderson PO","year":"1991","journal-title":"Clin Pharm"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809302700110"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-706X(03)00042-1"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4922(02)02386-3"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-706X(03)00036-6"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-706X(03)00031-7"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2002000200016"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/jaoac\/79.6.1281","article-title":"Rapid quantitative screening assay of trace benzimidazole residues in milk by liquid chromatography","volume":"79","author":"Fletouris D","year":"1996","journal-title":"J AOAC Int"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(91)80131-U"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0956-7135(99)00089-4"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(03)00034-6"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199018020-00005"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0022-3565(25)13115-7","article-title":"Active transport of cimetidine and ranitidine into the milk of Sprague Dawley rats","volume":"277","author":"McNamara PJ","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.003319"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00397.2005"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2008.08.007"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00170.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1997.00625.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(01)80094-1"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2002000200016"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(03)00369-7"},{"key":"e_1_2_6_30_2","unstructured":"MEDSAFE.Information for health professionals. Available athttp:\/\/www.medsafe.govt.nz\/Profs\/PUarticles\/lactation.htm#Calculation(last accessed 15 May 2008)."},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.355"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.3.776"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)08325-6"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/124.8.1199"},{"key":"e_1_2_6_35_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/09637489709006966","article-title":"Relationships between soil\u2010transmitted helminthiases and growth in urban slum school children in Ujung Pandang, Indonesia","volume":"48","author":"Hadju V","year":"1997","journal-title":"Int J Food Sci Nutr"},{"key":"e_1_2_6_36_2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(98)00027-0","article-title":"Albendazole for mass treatment of asymptomatic trichuris infections","volume":"352","author":"Winstanley P","year":"1998","journal-title":"Lancet"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2009.03524.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2009.03524.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T18:14:37Z","timestamp":1739297677000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2009.03524.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1365-2125.2009.03524.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03524.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}